FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975419073> ?p ?o ?g. }

• W1975419073 endingPage "170" @default.
• W1975419073 startingPage "145" @default.
• W1975419073 abstract "The role of oncoproteins and tumor suppressor proteins in promoting the malignant transformation of mammalian cells by affecting properties such as proliferative signalling, cell cycle regulation and altered adhesion is well established. Chemicals, viruses and radiation are also generally accepted as agents that commonly induce mutations in the genes encoding these cancer-causing proteins, thereby giving rise to cancer. However, more recent evidence indicates the importance of two additional key factors imposed on proliferating cells that are involved in transformation to malignancy and these are hypoxia and/or stressful conditions of nutrient deprivation (e.g. lack of glucose). These two additional triggers can initiate and promote the process of malignant transformation when a low percentage of cells overcome and escape cellular senescence. It is becoming apparent that hypoxia causes the progressive elevation in mitochondrial ROS production (chronic ROS) which over time leads to stabilization of cells via increased HIF-2alpha expression, enabling cells to survive with sustained levels of elevated ROS. In cells under hypoxia and/or low glucose, DNA mismatch repair processes are repressed by HIF-2alpha and they continually accumulate mitochondrial ROS-induced oxidative DNA damage and increasing numbers of mutations driving the malignant transformation process. Recent evidence also indicates that the resulting mutated cancer-causing proteins feedback to amplify the process by directly affecting mitochondrial function in combinatorial ways that intersect to play a major role in promoting a vicious spiral of malignant cell transformation. Consequently, many malignant processes involve periods of increased mitochondrial ROS production when a few cells survive the more common process of oxidative damage induced cell senescence and death. The few cells escaping elimination emerge with oncogenic mutations and survive to become immortalized tumors. This review focuses on evidence highlighting the role of mitochondria as drivers of elevated ROS production during malignant transformation and hence, their potential as targets for cancer therapy. The review is organized into five main sections concerning different aspects of mitochondrial malignancy. The first concerns the functions of mitochondrial ROS and its importance as a pacesetter for cell growth versus senescence and death. The second considers the available evidence that cellular stress in the form of hypoxic and/or hypoglycaemic conditions represent two of the major triggering events for cancer and how oncoproteins reinforce this process by altering gene expression to bring about a common set of changes in mitochondrial function and activity in cancer cells. The third section presents evidence that oncoproteins and tumor suppressor proteins physically localize to the mitochondria in cancer cells where they directly regulate malignant mitochondrial programs, including apoptosis. The fourth section covers common mutational changes in the mitochondrial genome as they relate to malignancy and the relationship to the other three areas. The last section concerns the relevance of these findings, their importance and significance for novel targeted approaches to anti-cancer therapy and selective triggering in cancer cells of the mitochondrial apoptotic pathway." @default.
• W1975419073 created "2016-06-24" @default.
• W1975419073 creator A5002401572 @default.
• W1975419073 creator A5013209374 @default.
• W1975419073 creator A5021751498 @default.
• W1975419073 creator A5060128303 @default.
• W1975419073 creator A5082131007 @default.
• W1975419073 date "2010-04-01" @default.
• W1975419073 modified "2023-10-18" @default.
• W1975419073 title "The causes of cancer revisited: “Mitochondrial malignancy” and ROS-induced oncogenic transformation – Why mitochondria are targets for cancer therapy" @default.
• W1975419073 cites W1523565294 @default.
• W1975419073 cites W1589792898 @default.
• W1975419073 cites W1675006565 @default.
• W1975419073 cites W1876742335 @default.
• W1975419073 cites W1921965616 @default.
• W1975419073 cites W1939228490 @default.
• W1975419073 cites W1964952409 @default.
• W1975419073 cites W1965254413 @default.
• W1975419073 cites W1966973624 @default.
• W1975419073 cites W1967072539 @default.
• W1975419073 cites W1967195358 @default.
• W1975419073 cites W1968965407 @default.
• W1975419073 cites W1970572439 @default.
• W1975419073 cites W1970766774 @default.
• W1975419073 cites W1970829588 @default.
• W1975419073 cites W1971082641 @default.
• W1975419073 cites W1971209629 @default.
• W1975419073 cites W1971832552 @default.
• W1975419073 cites W1972783950 @default.
• W1975419073 cites W1972871470 @default.
• W1975419073 cites W1973085272 @default.
• W1975419073 cites W1974879138 @default.
• W1975419073 cites W1975009275 @default.
• W1975419073 cites W1975750728 @default.
• W1975419073 cites W1976610991 @default.
• W1975419073 cites W1977423644 @default.
• W1975419073 cites W1978214583 @default.
• W1975419073 cites W1979264220 @default.
• W1975419073 cites W1979526109 @default.
• W1975419073 cites W1980385765 @default.
• W1975419073 cites W1983827654 @default.
• W1975419073 cites W1984636849 @default.
• W1975419073 cites W1985191673 @default.
• W1975419073 cites W1985929809 @default.
• W1975419073 cites W1986198814 @default.
• W1975419073 cites W1987546235 @default.
• W1975419073 cites W1987711340 @default.
• W1975419073 cites W1988811375 @default.
• W1975419073 cites W1988943327 @default.
• W1975419073 cites W1990380599 @default.
• W1975419073 cites W1990412352 @default.
• W1975419073 cites W1990458209 @default.
• W1975419073 cites W1990991567 @default.
• W1975419073 cites W1991324349 @default.
• W1975419073 cites W1995562352 @default.
• W1975419073 cites W1997813173 @default.
• W1975419073 cites W1998767677 @default.
• W1975419073 cites W2001457226 @default.
• W1975419073 cites W2002285022 @default.
• W1975419073 cites W2002936090 @default.
• W1975419073 cites W2003667906 @default.
• W1975419073 cites W2005139419 @default.
• W1975419073 cites W2005627263 @default.
• W1975419073 cites W2006708642 @default.
• W1975419073 cites W2007244362 @default.
• W1975419073 cites W2007468662 @default.
• W1975419073 cites W2007534790 @default.
• W1975419073 cites W2008971389 @default.
• W1975419073 cites W2009080781 @default.
• W1975419073 cites W2009202499 @default.
• W1975419073 cites W2009515439 @default.
• W1975419073 cites W2009685570 @default.
• W1975419073 cites W2010077871 @default.
• W1975419073 cites W2011892634 @default.
• W1975419073 cites W2012796327 @default.
• W1975419073 cites W2012800478 @default.
• W1975419073 cites W2014793391 @default.
• W1975419073 cites W2015859699 @default.
• W1975419073 cites W2015873509 @default.
• W1975419073 cites W2017692041 @default.
• W1975419073 cites W2018951168 @default.
• W1975419073 cites W2023083086 @default.
• W1975419073 cites W2023373433 @default.
• W1975419073 cites W2023538913 @default.
• W1975419073 cites W2024163261 @default.
• W1975419073 cites W2024235550 @default.
• W1975419073 cites W2025818978 @default.
• W1975419073 cites W2026152516 @default.
• W1975419073 cites W2027253055 @default.
• W1975419073 cites W2028339345 @default.
• W1975419073 cites W2029597518 @default.
• W1975419073 cites W2032082852 @default.
• W1975419073 cites W2032533550 @default.
• W1975419073 cites W2032811482 @default.
• W1975419073 cites W2033713408 @default.
• W1975419073 cites W2034246810 @default.
• W1975419073 cites W2035420700 @default.
• W1975419073 cites W2036223398 @default.

• next